Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lineage Cell Therapeutics stock | $2.35

Learn how to easily invest in Lineage Cell Therapeutics stock.

Lineage Cell Therapeutics Inc is a biotechnology business based in the US. Lineage Cell Therapeutics shares (LCTX) are listed on the NYSE MKT and all prices are listed in US Dollars. Lineage Cell Therapeutics employs 49 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Lineage Cell Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LCTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lineage Cell Therapeutics stock price (NYSE MKT: LCTX)

Use our graph to track the performance of LCTX stocks over time.

Lineage Cell Therapeutics shares at a glance

Information last updated 2021-10-25.
Latest market close$2.35
52-week range$1.01 - $3.13
50-day moving average $2.44
200-day moving average $2.56
Wall St. target price$6.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.08

Buy Lineage Cell Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lineage Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lineage Cell Therapeutics price performance over time

Historical closes compared with the close of $2.35 from 2021-10-22

1 week (2021-10-18) 3.07%
1 month (2021-09-24) -8.56%
3 months (2021-07-26) -10.98%
6 months (2021-04-26) -9.62%
1 year (2020-10-23) 86.51%
2 years (2019-10-25) 175.79%
3 years (2018-10-25) 16.92%
5 years (2016-10-25) 3.5

Lineage Cell Therapeutics financials

Revenue TTM $1.8 million
Gross profit TTM $1.4 million
Return on assets TTM -13.19%
Return on equity TTM -10.82%
Profit margin 0%
Book value $0.75
Market capitalisation $393.5 million

TTM: trailing 12 months

Shorting Lineage Cell Therapeutics shares

There are currently 8.8 million Lineage Cell Therapeutics shares held short by investors – that's known as Lineage Cell Therapeutics's "short interest". This figure is 15.6% up from 7.6 million last month.

There are a few different ways that this level of interest in shorting Lineage Cell Therapeutics shares can be evaluated.

Lineage Cell Therapeutics's "short interest ratio" (SIR)

Lineage Cell Therapeutics's "short interest ratio" (SIR) is the quantity of Lineage Cell Therapeutics shares currently shorted divided by the average quantity of Lineage Cell Therapeutics shares traded daily (recently around 965155.81140351). Lineage Cell Therapeutics's SIR currently stands at 9.12. In other words for every 100,000 Lineage Cell Therapeutics shares traded daily on the market, roughly 9120 shares are currently held short.

However Lineage Cell Therapeutics's short interest can also be evaluated against the total number of Lineage Cell Therapeutics shares, or, against the total number of tradable Lineage Cell Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lineage Cell Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Lineage Cell Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0699% of the tradable shares (for every 100,000 tradable Lineage Cell Therapeutics shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Lineage Cell Therapeutics.

Find out more about how you can short Lineage Cell Therapeutics stock.

Lineage Cell Therapeutics share dividends

We're not expecting Lineage Cell Therapeutics to pay a dividend over the next 12 months.

Have Lineage Cell Therapeutics's shares ever split?

Lineage Cell Therapeutics's shares were split on a 3:1 basis on 30 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lineage Cell Therapeutics shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lineage Cell Therapeutics shares which in turn could have impacted Lineage Cell Therapeutics's share price.

Lineage Cell Therapeutics share price volatility

Over the last 12 months, Lineage Cell Therapeutics's shares have ranged in value from as little as $1.01 up to $3.13. A popular way to gauge a stock's volatility is its "beta".

LCTX.US volatility(beta: 1.83)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Lineage Cell Therapeutics's is 1.8317. This would suggest that Lineage Cell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lineage Cell Therapeutics overview

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd.

Frequently asked questions

What percentage of Lineage Cell Therapeutics is owned by insiders or institutions?
Currently 4.509% of Lineage Cell Therapeutics shares are held by insiders and 43.945% by institutions.
How many people work for Lineage Cell Therapeutics?
Latest data suggests 49 work at Lineage Cell Therapeutics.
When does the fiscal year end for Lineage Cell Therapeutics?
Lineage Cell Therapeutics's fiscal year ends in December.
Where is Lineage Cell Therapeutics based?
Lineage Cell Therapeutics's address is: 2173 Salk Avenue, Carlsbad, CA, United States, 92008
What is Lineage Cell Therapeutics's ISIN number?
Lineage Cell Therapeutics's international securities identification number is: US53566P1093
What is Lineage Cell Therapeutics's CUSIP number?
Lineage Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09066L105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site